[ad_1]
“Before any vaccine and any drug (against coronavirus) can be licensed, a series of tests and trials need to be carried out,” WHO spokesman Christian Lindmeier was quoted as saying by the French daily Le Figaro.
“Sometimes individual researchers say they have discovered something. This news is certainly excellent, “said WHO spokesman Ch. Lindmeier.
However, Ch. According to Lindmeier, “There is a big difference between ‘finding’ or ‘having’ an effective vaccine and completing all the steps (of testing the vaccine).
“There are basic principles and clear instructions, normative acts so that everything is safe and effective,” he stressed.
On Monday, the head of the Russian direct investment fund Kirill Dmitryev announced that a Russian vaccine against the coronavirus should be registered within ten days.
“If this happens in the next ten days, we will outperform not only the United States but also other countries, as this will be the first coronavirus vaccine to be registered,” he said.
Earlier, Russian Health Minister Mikhail Murashka said that mass production of the vaccine, developed at the National Center for Epidemiological and Microbiological Research in Gamalaya, could begin in October.
Russia said Monday its goal is to begin mass production of the coronavirus vaccine next month and increase production to “several million” doses a month next year.
The country is conducting studies on various vaccine prototypes. The Gamalaya National Center for Epidemiological and Microbiological Research in Moscow has already reached the final stage of developing its vaccine.
“We are very hopeful to start mass production in September,” Industry and Trade Minister Denis Manturov was quoted as saying by TASS news agency.
“We will be able to ensure the production of several hundred thousand doses a month. At the beginning of next year, production will increase to several million doses (per month),” he said, adding that a manufacturer is preparing production technology in three locations. in central Russia.
Health Minister Mikhail Murashka announced on Saturday that clinical trials of a coronavirus vaccine being developed at the Gamalea Center have already been completed and the necessary documents are currently being prepared for its registration.
The National Center for Virology and Biotechnology, Vektor, is currently conducting clinical trials of another prototype of the vaccine, and is scheduled to begin testing two more prototypes of the vaccine in humans over the next two months, the minister said.
The Gamalea Institute’s vaccine is of the vector type, which is another virus that carries RNA of the causative agent of the COVID-19 coronavirus infection to stimulate an immune response in the cells of the human body.
Adenoviruses are used as vectors for the transmission of the genetic material of the coronavirus. In this sense, the vaccine prototype developed by the Gamalea Center is similar to that developed by the Chinese pharmaceutical company CanSino, whose clinical trials are already well advanced.
The Gamalea Center was criticized when its scientists and directors launched a prototype of the vaccine a few months ago. Critics say such a move goes against normal practice and is a hasty way to begin human testing.
The scientists told the AFP news agency that it will be difficult for Russia to start mass production of the vaccine because the country lacks raw materials, adequate equipment and experience, especially with advanced technologies such as viral vectors.
Some Russian officials boasted that the country would be the first country in the world to develop a coronavirus vaccine, and even compared it to the last century’s space race between the Soviet Union and the United States over the launch of the first artificial ground satellite to the space.
Moscow has rejected accusations by the United Kingdom, the United States and Canada that a group of programmers linked to Russian intelligence from Western laboratories have tried to steal information about the coronavirus vaccine.
Russia currently ranks fourth in the world in terms of the number of detected cases of coronavirus infection, after the United States, Brazil and India.
The Russian vaccine is not on the WHO vaccine list, which registers six vaccines whose development has reached the third stage of clinical trials. During this phase, numerous tests are being carried out in humans.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any form without consent, and if consent has been obtained, DELFI should be cited as the source.
[ad_2]
